4887 Stock Overview
Sawai Group Holdings Co., Ltd., together with subsidiaries, engages in the research and development, manufacturing, and marketing of generic pharmaceuticals.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Sawai Group Holdings Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥6,124.00 |
| 52 Week High | JP¥6,498.00 |
| 52 Week Low | JP¥3,255.00 |
| Beta | 0.24 |
| 1 Month Change | 1.42% |
| 3 Month Change | 8.50% |
| 1 Year Change | 59.69% |
| 3 Year Change | 17.54% |
| 5 Year Change | 2.75% |
| Change since IPO | 292.56% |
Recent News & Updates
Is There An Opportunity With Sawai Group Holdings Co., Ltd.'s (TSE:4887) 41% Undervaluation?
Apr 22
Is Sawai Group Holdings (TSE:4887) A Risky Investment?
Mar 06Shareholder Returns
| 4887 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | 5.0% | 1.1% | -1.0% |
| 1Y | 59.7% | 3.7% | 27.9% |
Return vs Industry: 4887 exceeded the JP Pharmaceuticals industry which returned 3.7% over the past year.
Return vs Market: 4887 exceeded the JP Market which returned 27.9% over the past year.
Price Volatility
| 4887 volatility | |
|---|---|
| 4887 Average Weekly Movement | 4.3% |
| Pharmaceuticals Industry Average Movement | 3.7% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in JP Market | 8.1% |
| 10% least volatile stocks in JP Market | 2.2% |
Stable Share Price: 4887 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4887's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1929 | 3,393 | Mitsuo Sawai | www.sawaigroup.holdings |
Sawai Group Holdings Co., Ltd., together with subsidiaries, engages in the research and development, manufacturing, and marketing of generic pharmaceuticals. The company offers generic drugs in various dosage forms, including tablets, oral dispersing tablets, capsules, granules, injectables, tapes, ophthalmic or nasal solutions, syrups, and other forms for various therapeutic areas comprising cardiovascular, gastro-intestinal, blood/body fluid, other metabolic, antibiotics, central nervous system, antiallergics, anti-cancer, urogenital organs and anus, chemotherapeutic and antineoplastic agents, respiratory system, etc., as well as vitamin preparations. It sells its generic drugs through distributors, wholesalers, and retailers in Japan and the United States.
Sawai Group Holdings Co., Ltd. Fundamentals Summary
| 4887 fundamental statistics | |
|---|---|
| Market cap | JP¥271.45b |
| Earnings (TTM) | JP¥17.71b |
| Revenue (TTM) | JP¥185.31b |
15.1x
P/E Ratio1.4x
P/S RatioIs 4887 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4887 income statement (TTM) | |
|---|---|
| Revenue | JP¥185.31b |
| Cost of Revenue | JP¥128.96b |
| Gross Profit | JP¥56.35b |
| Other Expenses | JP¥38.64b |
| Earnings | JP¥17.71b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 13, 2024
| Earnings per share (EPS) | 404.29 |
| Gross Margin | 30.41% |
| Net Profit Margin | 9.56% |
| Debt/Equity Ratio | 41.1% |
How did 4887 perform over the long term?
See historical performance and comparison